By Stefanie Johns, PhD, Director of Regulatory Affairs, Kymanox Corporation

Drug delivery methods present considerable challenges to the development of gene therapies, including difficulties in accessing the therapeutic target, prevention of degradation, and facilitation of drug activity to achieve its intended purpose. Even one of the most popular delivery methods, adeno-associated virus (AAV)-based technology, poses serious risk to patient safety through severe adverse side effects.

Read More